Company Vivoryon Therapeutics AG Euronext Amsterdam
Equities
DE0007921835
Biotechnology & Medical Research
Business Summary
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutic Products
100.0
%
| 0 | nan % | -4 | 100.0 % | - |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Germany
100.0
%
| 0 | nan % | -4 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Director/Board Member | 56 | 18-08-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 74 | 06-12-31 | |
Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
Samir Shah
BRD | Director/Board Member | 63 | 21-12-31 |
Director/Board Member | 56 | 18-08-30 | |
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Claudia Riedl
BRD | Director/Board Member | 54 | 21-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 26,066,808 | 17,348,972 ( 66.56 %) | 0 | 66.56 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |